Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence?-Implications for a Risk-adapted Follow-up Strategy

被引:24
作者
Ahove, Deborah A.
Hoffman, Karen E.
Hu, Jim C.
Choueiri, Toni K.
D'Amico, Anthony V.
Nguyen, Paul L. [1 ]
机构
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
关键词
RANDOMIZED CLINICAL-TRIAL; DISEASE RECURRENCE; POSTOPERATIVE NOMOGRAM; BIOCHEMICAL RECURRENCE; ADJUVANT RADIOTHERAPY; SALVAGE RADIOTHERAPY; CANCER; UPDATE;
D O I
10.1016/j.urology.2010.03.092
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
OBJECTIVES To determine the predictors of late prostate-specific antigen (PSA) failure among men with an undetectable PSA level 5 years after radical prostatectomy (RP). METHODS A total of 505 men who had undergone RP for prostate cancer from 1985 to 2000 at Brigham and Women's Hospital and who had >= 5 years of recurrence-free survival (ie, all PSA levels < 0.2 ng/mL) constituted the study cohort. Cox multivariate regression analysis was used to determine the factors associated with PSA failure after 5 years. Kaplan-Meier analysis was used to estimate the PSA failure-free survival rate. RESULTS The median follow-up was 10.7 years after RP (interquartile range 7.8-13.3). No patient had PSA failure at year 5, but the PSA failure-free survival rate for this cohort at year 10 was 88% (95% confidence interval 84.4%-91.0%) and, at year 13, was 82% (95% confidence interval 77.0%-86.0%). On multivariable regression analysis, the factors associated with failure after year 5 were Gleason score 7 (adjusted hazard ratio [AHR] 1.88, P = .036), Gleason score 8-10 (AHR 4.81, P = .002), extracapsular extension (AHR 2.37, P = .003), and seminal vesicle invasion (AHR 1.52, P = .062). CONCLUSIONS Among men with an undetectable PSA level 5 years after RP, Gleason score 7, Gleason score 8-10, extracapsular extension, and seminal vesicle invasion were significant predictors of subsequent late PSA failure. Patients with these factors (particularly Gleason score 8-10 or seminal vesicle invasion) should have continued close monitoring of their PSA level and consideration of early salvage, as appropriate. However, patients with Gleason score 6 disease were very unlikely to develop late recurrence and might be candidates for less-intense follow-up once they have passed the 5-year mark. UROLOGY 76: 1201-1205, 2010. (C) 2010 Elsevier Inc.
引用
收藏
页码:1201 / 1205
页数:5
相关论文
共 16 条
[1]
Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].
Bolla, M ;
van Poppel, H ;
Collette, L ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
van Velthoven, R ;
Maréchal, JM ;
Scalliet, P ;
Haustermans, K ;
Piérart, M .
LANCET, 2005, 366 (9485) :572-578
[2]
Prostate cancer nomograms: An update [J].
Chun, Felix K. -H. ;
Karakiewicz, Pierre I. ;
Briganti, Alberto ;
Gallina, Andrea ;
Kattan, Michael W. ;
Montorsi, Francesco ;
Huland, Hartwig ;
Graefen, Markus .
EUROPEAN UROLOGY, 2006, 50 (05) :914-926
[3]
Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: Results from a 10-year cohort analysis [J].
Coen, JJ ;
Chung, CS ;
Shipley, WU ;
Zietman, AL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03) :621-628
[4]
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes [J].
Cookson, Michael S. ;
Aus, Gunnar ;
Burnett, Arthur L. ;
Canby-Hagino, Edith D. ;
D'Amico, Anthony V. ;
Dmochowski, Roger R. ;
Eton, David T. ;
Forman, Jeffrey D. ;
Goldenberg, S. Larry ;
Hernandez, Javier ;
Higano, Celestia S. ;
Kraus, Stephen R. ;
Moul, Judd W. ;
Tangen, Catherine ;
Thrasher, J. Brantley ;
Thompson, Ian .
JOURNAL OF UROLOGY, 2007, 177 (02) :540-545
[5]
Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer [J].
Diblasio, CJ ;
Kattan, MW .
UROLOGY, 2003, 62 (6B) :9-18
[6]
NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer [J].
Kattan, MW ;
Wheeler, TM ;
Scardino, PT .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1499-1507
[8]
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer [J].
Kattan, MW ;
Eastham, JA ;
Stapleton, AMF ;
Wheeler, TM ;
Scardino, PT .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (10) :766-771
[9]
Mohler J, 2010, J NATL COMPR CANC NE, V8, P162, DOI 10.6004/jnccn.2010.0012
[10]
Prognostic importance of Comorbidity in a hospital-based cancer registry [J].
Piccirillo, JF ;
Tierney, RM ;
Costas, I ;
Grove, L ;
Spitznagel, EL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (20) :2441-2447